Esperion Therapeutics (ESPR) Other Non-Current Assets (2019 - 2022)
Historic Other Non-Current Assets for Esperion Therapeutics (ESPR) over the last 4 years, with Q3 2022 value amounting to $50.0 million.
- Esperion Therapeutics' Other Non-Current Assets changed 0.0% to $50.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $50.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $50.0 million for FY2021, which is N/A changed from last year.
- Per Esperion Therapeutics' latest filing, its Other Non-Current Assets stood at $50.0 million for Q3 2022, which was down 0.0% from $50.0 million recorded in Q2 2022.
- In the past 5 years, Esperion Therapeutics' Other Non-Current Assets ranged from a high of $50.0 million in Q3 2021 and a low of $928000.0 during Q2 2019
- For the 4-year period, Esperion Therapeutics' Other Non-Current Assets averaged around $23.3 million, with its median value being $1.3 million (2020).
- The largest annual percentage gain for Esperion Therapeutics' Other Non-Current Assets in the last 5 years was 3943.97% (2020), contrasted with its biggest fall of 2221.29% (2020).
- Esperion Therapeutics' Other Non-Current Assets (Quarter) stood at $928000.0 in 2019, then skyrocketed by 39.44% to $1.3 million in 2020, then skyrocketed by 3763.99% to $50.0 million in 2021, then changed by 0.0% to $50.0 million in 2022.
- Its Other Non-Current Assets stands at $50.0 million for Q3 2022, versus $50.0 million for Q2 2022 and $50.0 million for Q1 2022.